CYD-TDV

AXP000206.1 · Vaccine

Platform
chimeric yellow fever 17D-dengue virus (ChimeriVax, tetravalent)
Targets
DENV-1 prM/E; DENV-2 prM/E; DENV-3 prM/E; DENV-4 prM/E
Originator
Mahidol University / Sanofi Pasteur
Sponsor
Sanofi Pasteur

Names

NameTypeSource
CYD-TDVpreferred name, codecurator, curator
Dengvaxiabrandcurator
Dengue Tetravalent Vaccine, Live ambiguoussynonymfda

Virus

Role
Vaccine vector
Family
Flaviviridae
Virus
yellow fever virus (NCBI Taxonomy 11089)
Strain
17D-204 backbone (CYD-1 to CYD-4 chimeras)
Replication
replicating
Modifications
prM and E genes of YF 17D-204 replaced by those of dengue virus serotypes 1, 2, 3 and 4 in four chimeric viruses
Transgenes
DENV-1 prM/E, DENV-2 prM/E, DENV-3 prM/E, DENV-4 prM/E
Route
subcutaneous
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
EMAEU2018-12-12approvedDengvaxiaPrevention of dengue disease caused by serotypes 1-4 in people aged 6-45 with confirmed previous dengue infectionsource
FDAUS2019-05-01approvedDengvaxiaPrevention of dengue disease caused by serotypes 1-4 in people with laboratory-confirmed previous dengue infection living in endemic areassource
EMAEU2025-10-21withdrawnDengvaxiaAuthorisation withdrawn at the holder's request; marketing permanently stopped for commercial reasonssource

Clinical trials (10)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04486638Dengvaxia US Pregnancy RegistryRecruiting2023-01-012029-06-30500Dengue Virus Infection
NCT04023708Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During PregnancyCompleted2022-03-112023-03-27104Dengue Virus Infection
NCT04170140Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information UpdateCompleted2020-01-072020-03-05300Dengue Virus Infection
NCT03960385Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - BrazilCompleted2017-08-012020-03-011854Dengue
NCT02992418Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy SubjectsTerminatedPhase 32016-12-192019-12-10688Dengue Fever; Dengue Hemorrhagic Fever
NCT02948933Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue VaccineCompleted2016-12-142022-12-2230000Dengue Fever; Dengue Hemorrhagic Fever
NCT02993757Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®CompletedPhase 32016-12-012019-05-27528Dengue Fever; Dengue Hemorrhagic Fever; Human Papillomavirus Disease
NCT02979535Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®CompletedPhase 32016-11-162019-03-25480Dengue Fever; Dengue Hemorrhagic Fever; Human Papillomavirus Disease
NCT00993447Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin AmericaCompletedPhase 22009-102011-09600Dengue; Dengue Fever; Dengue Hemorrhagic Fever; Dengue Virus
NCT00842530Efficacy and Safety of Dengue Vaccine in Healthy ChildrenCompletedPhase 22009-022013-094002Dengue Diseases; Dengue Fever; Dengue Hemorrhagic Fever; Dengue Virus
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT03999996Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster DoseCompletedPhase 32019-11-122024-05-25365Dengue Fevername in intervention: Dengue Tetravalent Vaccine, Live

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41213642Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18-50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial.Human vaccines & immunotherapeutics2025name in title: CYD-TDV
PMID 34635391Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand.Human immunology2022name in abstract: CYD-TDV
PMID 35061851Pre-vaccination frequency of circulatory Tfh is associated with robust immune response to TV003 dengue vaccine.PLoS pathogens2022name in abstract: CYD-TDV
PMID 35364022Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.The Lancet. Infectious diseases2022name in title: CYD-TDV
PMID 35505623A cross-sectional survey to evaluate prescribers' knowledge and understanding of safety messages following Dengvaxia® product information update.Pharmacoepidemiology and drug safety2022cited by trial NCT04170140
PMID 35659904Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials.The Lancet. Microbe2022name in abstract: CYD-TDV
PMID 36068106Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia.Vaccine2022name in abstract: CYD-TDV
PMID 33212067Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.The Lancet. Infectious diseases2021name in title: CYD-TDV
PMID 33212068Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.The Lancet. Infectious diseases2021name in abstract: CYD-TDV
PMID 33369671Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries.Transactions of the Royal Society of Tropical Medicine and Hygiene2021name in abstract: CYD-TDV
PMID 33626291Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.Human vaccines & immunotherapeutics2021name in abstract: CYD-TDV
PMID 33822015Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2021cited by trial NCT00842530
PMID 33992441Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico.Vaccine2021cited by trial NCT02979535
PMID 34003796Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection.The Journal of clinical investigation2021name in abstract: Dengvaxia
PMID 34117198Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine: Randomized Phase IIIb Trial in Healthy Participants 9-60 Years of Age in the Philippines.The Pediatric infectious disease journal2021cited by trial NCT02992418
PMID 34250977Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9-13 Years of Age in Malaysia: A Phase IIIb, Randomized, Open-label Study.The Pediatric infectious disease journal2021cited by trial NCT02993757
PMID 34367162Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections.Frontiers in immunology2021name in abstract: Dengvaxia
PMID 31464558Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series.Human vaccines & immunotherapeutics2020name in abstract: Dengvaxia
PMID 31755526The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States.The Journal of infectious diseases2020name in abstract: Dengvaxia
PMID 32040014Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.The Pediatric infectious disease journal2020name in abstract: CYD-TDV
PMID 32542024Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America.PloS one2020name in title: CYD-TDV
PMID 32932330Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.The Pediatric infectious disease journal2020cited by trial NCT00993447
PMID 30724660Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.Human vaccines & immunotherapeutics2019name in title: CYD-TDV
PMID 30986790Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America: Evaluation 4-5 Years After a Primary 3-Dose Schedule.The Pediatric infectious disease journal2019name in abstract: Dengvaxia
PMID 31115304Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.The American journal of tropical medicine and hygiene2019name in abstract: CYD-TDV
PMID 29194547Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.The Journal of infectious diseases2018name in abstract: CYD-TDV
PMID 29300876Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2018name in abstract: Dengvaxia
PMID 29573874A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia.Vaccine2018name in title: Dengvaxia
PMID 29716774Dengue vaccination during pregnancy - An overview of clinical trials data.Vaccine2018name in abstract: CYD-TDV
PMID 29897841Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.The New England journal of medicine2018cited by trial NCT00842530
PMID 30127007Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials.Proceedings of the National Academy of Sciences of the United States of America2018name in abstract: CYD-TDV
PMID 30194294Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning.Nature communications2018name in title: CYD-TDV
PMID 30241510Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.BMC infectious diseases2018name in abstract: CYD-TDV
PMID 30543657Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease.PloS one2018name in abstract: CYD-TDV
PMID 27932620Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.The Journal of infectious diseases2017name in title: CYD-TDV
PMID 28067718Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.The Pediatric infectious disease journal2017name in abstract: CYD-TDV
PMID 28968794Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.The Journal of infectious diseases2017name in title: CYD-TDV
PMID 29141713Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine.The American journal of tropical medicine and hygiene2017name in abstract: CYD-TDV
PMID 26291554Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.Human vaccines & immunotherapeutics2016name in abstract: CYD-TDV
PMID 26836763A comparative study on active and passive epidemiological surveillance for dengue in five countries of Latin America.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2016name in abstract: CYD-TDV
PMID 27102820Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction.Vaccine2016cited by trial NCT00842530
PMID 27254034Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru: A Randomized Trial.The Pediatric infectious disease journal2016name in abstract: CYD-TDV
PMID 27414655Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.PLoS neglected tropical diseases2016name in abstract: CYD-TDV
PMID 27459266Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.PLoS neglected tropical diseases2016name in abstract: CYD-TDV
PMID 25365753Efficacy of a tetravalent dengue vaccine in children in Latin America.The New England journal of medicine2015name in abstract: CYD-TDV
PMID 25966916First Experience of Concomitant Vaccination Against Dengue and MMR in Toddlers.The Pediatric infectious disease journal2015name in abstract: CYD-TDV
PMID 26214039Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.The New England journal of medicine2015cited by trial NCT00842530
PMID 26279339Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.Vaccine2015name in abstract: CYD-TDV
PMID 25018116Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.Lancet (London, England)2014name in abstract: CYD-TDV
PMID 25483647Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.Human vaccines & immunotherapeutics2014name in abstract: CYD-TDV
PMID 23540847Efficacy of tetravalent dengue vaccine in Thai schoolchildren - Authors' reply.Lancet (London, England)2013cited by trial NCT00842530
PMID 23839107Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore.Human vaccines & immunotherapeutics2013name in abstract: CYD-TDV
PMID 24021313Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.Vaccine2013name in abstract: CYD-TDV
PMID 24067553Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.The Pediatric infectious disease journal2013cited by trial NCT00993447
PMID 24135573Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.Vaccine2013name in abstract: CYD-TDV
PMID 24189367Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil.The American journal of tropical medicine and hygiene2013name in abstract: CYD-TDV
PMID 22863660Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.Vaccine2012name in abstract: CYD-TDV
PMID 22894958Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.Human vaccines & immunotherapeutics2012name in title: CYD-TDV
PMID 22975340Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.Lancet (London, England)2012cited by trial NCT00842530

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 39871573Achievements and Approaches in the Search for Small-Molecule Dengue NS2B/NS3 Inhibitors.Current medicinal chemistry2026name in abstract: Dengvaxia
PMID 40794141Dengue Vaccines.Current topics in microbiology and immunology2026name in abstract: Dengvaxia
PMID 41201140Global epidemiology of dengue in paediatric and adolescent populations: a systematic review and meta-analysis.Infectious diseases (London, England)2026name in abstract: CYD-TDV
PMID 41548813Animal models illuminate dengue immunopathogenesis to guide vaccine and therapeutic developments.Journal of virological methods2026name in abstract: Dengvaxia
PMID 41557736Bridging the knowledge gap: Thai parents' perspectives on dengue infection and its vaccination and the need for targeted promotion.PLoS neglected tropical diseases2026name in abstract: Dengvaxia
PMID 41577185Current status of dengue fever epidemics and vaccine development.Virologica Sinica2026name in abstract: Dengvaxia
PMID 41579705Preclinical evaluation of DENV1 mRNA vaccines in mice: Toward improved neutralizing antibody and T cell responses.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2026name in abstract: Dengvaxia
PMID 41619542Barriers to dengue vaccine coverage in low- and middle-income countries (LMICs).Virology2026name in abstract: Dengvaxia
PMID 41662753Dengue Vaccine Effectiveness: Results from a 6-Year Population-Based Cohort Study in Southern Brazil.The American journal of tropical medicine and hygiene2026name in abstract: Dengvaxia
PMID 41723069Adverse events following dengue vaccine (Dengvaxia) reported to the Vaccine Adverse Event Reporting System (VAERS), 2019-2025.Vaccine2026name in title: Dengvaxia
PMID 41800104Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database.Frontiers in pharmacology2026name in title: CYD-TDV
PMID 41842965Safety of a tetravalent live dengue virus vaccine in children responding to one serotype only.JCI insight2026name in abstract: Dengvaxia
PMID 41867205Inactivated Japanese encephalitis virus vaccination imprints fusion loop-biased antibody responses that are attenuated by repeated live-attenuated dengue vaccination.medRxiv : the preprint server for health sciences2026name in abstract: CYD-TDV
PMID 41959375CD8+ T cells and Humoral Immunity Influence the Development of Antibody-Dependent Enhancement: Implications for Vaccine Design.bioRxiv : the preprint server for biology2026name in abstract: Dengvaxia
PMID 42296464Dengue and chikungunya vaccines past, present and future: implications for travelers.Current opinion in infectious diseases2026name in abstract: CYD-TDV
PMID 42507508Advanced next-generation vaccines for dengue and other flaviviral infections.Journal of vector borne diseases2026name in abstract: Dengvaxia
PMID 42537921Neutralizing dengue antibodies after 10 years of the chimeric yellow fever tetravalent dengue vaccine (CYD-TDV) and dengue antibody cross-reactivity with SARS-CoV-2 in Indonesia.Acta tropica2026name in title: CYD-TDV
PMID 42670066Prevention or Treatment of Dengue Virus Disease: An Update on Recent Vaccination and Therapeutics Globally.Combinatorial chemistry & high throughput screening2026name in abstract: Dengvaxia
PMID 42713475Update on efficacy, safety, and immunogenicity of Dengue vaccines: a systematic review and meta-analysis.Le infezioni in medicina2026name in abstract: Dengvaxia
PMID 42797550Dengue Vaccines in a Changing Epidemiological Landscape: Current Evidence, Unresolved Challenges, and Public Health Considerations.Vaccines2026name in abstract: CYD-TDV
PMID 42854934An overview of current technologies in the development of drugs and vaccines against dengue virus.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases2026name in abstract: Dengvaxia
PMID 42925565Recent Landscape in Dengue Vaccines: A Systematic Review and Meta-Analysis.Journal of vector borne diseases2026name in abstract: CYD-TDV
PMID 42927623Metabolic Screening and In Silico Investigation of Eucalyptus globulus Essential Oil Bioactives Against DENV-2 Envelope Protein.ChemistryOpen2026name in abstract: Dengvaxia
PMID 42931365Efficacy, Immunogenicity, Safety, and Evidence Independence of CYD-TDV and TAK-003 Dengue Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis.Vaccines2026name in title: CYD-TDV
PMID 42931431Immunological Challenges and Emerging Strategies in Dengue Virus Vaccine Development.Vaccines2026name in abstract: Dengvaxia
PMID 42947633A Live Attenuated Dengue Virus Vaccine (Dengvaxia) is Suppressed in Individuals with Immunity to Serotype 4.The Journal of infectious diseases2026name in title: Dengvaxia
PMID 42952807A single dose of Dengvaxia is associated with transient reduction in dengue infection risk among dengue-naïve children.Frontiers in immunology2026name in title: Dengvaxia
PMID 42988214Real-world Evidence on dengue vaccine effectiveness: a systematic review of post-licensure evidence and methodological gaps.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2026name in abstract: CYD-TDV
PMID 42993603CD8+ T cells and humoral immunity may mitigate the effects of antibody-dependent enhancement: implications for dengue vaccine design.Journal of virology2026name in abstract: Dengvaxia
PMID 39830640Current status of the development of dengue vaccines.Vaccine: X2025name in abstract: Dengvaxia
PMID 39976669Nano-interventions for dengue: a comprehensive review of control, detection and treatment strategies.Inflammopharmacology2025name in abstract: Dengvaxia
PMID 39995247Advances in the Epidemiology, Pathogenesis, Diagnostic Methods, and Vaccine Development of Dengue Fever: A Comprehensive Review.Viral immunology2025name in abstract: Dengvaxia
PMID 40006692Dengue Vaccination: A Practical Guide for Clinicians.Vaccines2025name in abstract: Dengvaxia
PMID 40014622Estimating per-infection cost and burden for dengue and Zika as a function of antibody-dependent enhancement.PLoS neglected tropical diseases2025name in abstract: Dengvaxia
PMID 40044132Advancements in dengue vaccines: A historical overview and pro-spects for following next-generation candidates.Journal of microbiology (Seoul, Korea)2025name in abstract: Dengvaxia
PMID 40109333Opportunities and challenges of mRNA technologies in development of dengue virus vaccine.Frontiers in immunology2025name in abstract: Dengvaxia
PMID 40183845Impact of ADE and Dengue Vaccination with Screening on Cost and Disease Burden for Homoserotypic Dengue and Zika.Bulletin of mathematical biology2025name in abstract: Dengvaxia
PMID 40195054Efficacy, Immune Response, and Safety of Dengue Vaccines in Adolescents: A Systematic Review.Reviews in medical virology2025name in abstract: Dengvaxia
PMID 40252364Knowledge-based mitigation of the environmental risk of Orthoflavivirus live-attenuated vaccines by targeting viral encoded determinants for the mosquito attenuated phenotype.Vaccine2025name in abstract: Dengvaxia
PMID 40266131The Genetic Evolution of DENV2 in the French Territories of the Americas: A Retrospective Study from the 2000s to the 2024 Epidemic, Including a Comparison of Amino Acid Changes with Vaccine Strains.Vaccines2025name in abstract: Dengvaxia
PMID 40279922Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: Final results of a 5-year case-control study.Vaccine2025name in abstract: Dengvaxia
PMID 40339179Rebuilding Public Trust: Factors Influencing Dengue Vaccine Uptake in the Aftermath of the Dengvaxia Controversy in the Philippines: A Partial Least Structural Equation Modeling Approach.Vaccine2025name in title: Dengvaxia
PMID 40432095Dengue Vaccine Development and Deployment into Routine Immunization.Vaccines2025name in abstract: Dengvaxia
PMID 40432141Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue.Vaccines2025name in abstract: Dengvaxia
PMID 40669253From controversy to confidence: Strengthening dengue vaccines safety reporting.Vaccine2025name in abstract: Dengvaxia
PMID 40734960Medical knowledge, political tension, and social relevance: a content and framing analysis of vaccine-related TV broadcasts in the Philippines.BMJ public health2025name in abstract: Dengvaxia
PMID 40862147The pre- and post-COVID-19 pandemic dengue fever patterns in southeastern coastal China in 2019 and 2024: molecular evolution and strain replacement.Frontiers in microbiology2025name in abstract: CYD-TDV
PMID 40969293Advancing dengue vaccine development: Challenges, innovations, and the path toward global protection.Pediatric investigation2025name in abstract: CYD-TDV
PMID 40975348A retrospective computational validation of a clinically evaluated recombinant envelope protein tetravalent dengue vaccine.International journal of biological macromolecules2025name in abstract: Dengvaxia
PMID 40981337State of the Art on Vaccine Development Against Dengue Infection: Scoping Review of the Literature.Infectious disease reports2025name in abstract: Dengvaxia
PMID 40991727Afucosylation of anti-dengue IgG is associated with enhanced susceptibility to dengue virus infection postvaccination.Science translational medicine2025name in abstract: Dengvaxia
PMID 41019525Pathophysiology and clinical implications of dengue-associated neurological disorders.Frontiers in microbiology2025name in abstract: Dengvaxia
PMID 41034330Structural and energetic basis of marine phytochemicals as dengue NS1 protein inhibitors.Scientific reports2025name in abstract: CYD-TDV
PMID 41086802Challenges in the Prevention and Treatment of Dengue Fever: An Emerging Issue.The American journal of tropical medicine and hygiene2025name in abstract: Dengvaxia
PMID 41287091Dengue vaccine effectiveness and safety: a systematic analysis of recent clinical trial data.Virology journal2025name in abstract: CYD-TDV
PMID 41295515Targeting Dendritic Cells with Virus-like Particles: Toward Safer and More Immunogenic Vaccines.Vaccines2025name in abstract: Dengvaxia
PMID 41441649Optimizing Humoral Immunity for Durable and Broad Protection in Flavivirus Vaccines.Vaccines2025name in abstract: CYD-TDV
PMID 37723635Development in the Inhibition of Dengue Proteases as Drug Targets.Current medicinal chemistry2024name in abstract: Dengvaxia
PMID 37859315Computational Advancement towards the Identification of Natural Inhibitors for Dengue Virus: A Brief Review.Combinatorial chemistry & high throughput screening2024name in abstract: Dengvaxia
PMID 37962048Exploring the Targets of Dengue Virus and Designs of Potential Inhibitors.Combinatorial chemistry & high throughput screening2024name in abstract: Dengvaxia
PMID 38331225Potential of several triazene derivatives against DENGUE viruses.Bioorganic & medicinal chemistry letters2024name in abstract: Dengvaxia
PMID 38350770Implications of information heard about Dengvaxia on Filipinos' perception on vaccination.Vaccine2024name in title: Dengvaxia
PMID 38391779Dengue Fever Epidemics and the Prospect of Vaccines: A Systematic Review and Meta-Analysis Using Clinical Trials in Children.Diseases (Basel, Switzerland)2024name in abstract: Dengvaxia
PMID 38527473Single dose of Dengvaxia vaccine: is it a cause for alarm?The Lancet. Infectious diseases2024name in title: Dengvaxia
PMID 38527474Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prospective, population-based cohort study.The Lancet. Infectious diseases2024name in abstract: CYD-TDV
PMID 38546211Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection.Journal of virology2024name in abstract: Dengvaxia
PMID 38579018Use of Dengvaxia® in Australian travellers: a case series.Journal of travel medicine2024name in title: Dengvaxia
PMID 38599678Perceptions of dengue risk and acceptability of a dengue vaccine in residents of Puerto Rico.Human vaccines & immunotherapeutics2024name in abstract: Dengvaxia
PMID 38616437Super epitope dengue vaccine instigated serotype independent immune protection in-silico.Vaccine2024name in abstract: Dengvaxia
PMID 38693800[Dengue vaccines, a time for cautious optimism?].Revue medicale suisse2024name in abstract: Dengvaxia
PMID 38712100Comparison of the Sensitivity and Specificity of Commercial Anti-Dengue Virus IgG Tests to Identify Persons Eligible for Dengue Vaccination.medRxiv : the preprint server for health sciences2024name in abstract: Dengvaxia
PMID 38793612Regional Variation of the CD4 and CD8 T Cell Epitopes Conserved in Circulating Dengue Viruses and Shared with Potential Vaccine Candidates.Viruses2024name in abstract: CYD-TDV
PMID 38807985Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia®) in the state of Paraná, Brazil: integrating case-cohort and case-control designs.Lancet regional health. Americas2024name in title: Dengvaxia
PMID 38845788Immunization against dengue virus infection is coercive: A timely call.Health science reports2024name in abstract: Dengvaxia
PMID 39194193Comparison of the sensitivity and specificity of commercial anti-dengue virus IgG tests to identify persons eligible for dengue vaccination.Journal of clinical microbiology2024name in abstract: Dengvaxia
PMID 39227968Trends and insights in dengue virus research globally: a bibliometric analysis (1995-2023).Journal of translational medicine2024name in abstract: Dengvaxia
PMID 39228383An effective pan-serotype dengue vaccine and enhanced control strategies could help in reducing the severe dengue burden in Bangladesh-A perspective.Frontiers in microbiology2024name in abstract: Dengvaxia
PMID 39336108An In Silico Design of a Vaccine against All Serotypes of the Dengue Virus Based on Virtual Screening of B-Cell and T-Cell Epitopes.Biology2024name in abstract: Dengvaxia
PMID 39463237Vaccination against dengue fever for travellers.Swiss medical weekly2024name in abstract: Dengvaxia
PMID 39543749Exploring plant-based dengue therapeutics: from laboratory to clinic.Tropical diseases, travel medicine and vaccines2024name in abstract: Dengvaxia
PMID 39626875Dengue and severe dengue with neurological complications: a challenge for prevention and control.Arquivos de neuro-psiquiatria2024name in abstract: Dengvaxia
PMID 39700304Genetic diversity of dengue virus circulating in the Philippines (2014-2019) and comparison with dengue vaccine strains.PLoS neglected tropical diseases2024name in abstract: Dengvaxia
PMID 39776767Machine learning and molecular docking prediction of potential inhibitors against dengue virus.Frontiers in chemistry2024name in abstract: Dengvaxia
PMID 40070980[Dengue fever vaccination Recommendations from the Société Francophone de Médecine Tropicale et de Santé Internationale for Metropolitan France and Overseas Territories].Medecine tropicale et sante internationale2024name in abstract: Dengvaxia
PMID 40093849Complexities of Dengue Fever: Pathogenesis, Clinical Features and Management Strategies.Discoveries (Craiova, Romania)2024name in abstract: Dengvaxia
PMID 36300833Filipinos' COVID-19 vaccine hesitancy comments in TikTok videos: A manifest content analysis.Public health nursing (Boston, Mass.)2023name in abstract: Dengvaxia
PMID 36417290Biologics for dengue prevention: up-to-date.Expert opinion on biological therapy2023name in abstract: Dengvaxia
PMID 36801791Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses.Bioorganic chemistry2023name in abstract: Dengvaxia
PMID 36857199Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art.The Journal of general virology2023name in abstract: Dengvaxia
PMID 36864886Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs. In vitro approach.Frontiers in cellular and infection microbiology2023name in abstract: Dengvaxia
PMID 36914616A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity.Nature communications2023name in abstract: Dengvaxia
PMID 36992414Molecular Mechanisms of Antiviral Agents against Dengue Virus.Viruses2023name in abstract: Dengvaxia
PMID 37114191A dengue vaccine whirlwind update.Therapeutic advances in infectious disease2023name in abstract: Dengvaxia
PMID 37158835Comparing the performance of dengue virus IgG and IgG-capture enzyme-linked immunosorbent assays in seroprevalence study.BMC infectious diseases2023name in abstract: Dengvaxia
PMID 37173267Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico.Vaccine2023name in abstract: CYD-TDV
PMID 37192141Epidemiologic Trends of Dengue in U.S. Territories, 2010-2020.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)2023name in abstract: Dengvaxia
PMID 37213267Identifying and Managing Vector-Borne Diseases in Migrants and Recent Travelers in the Emergency Department.Current emergency and hospital medicine reports2023name in abstract: Dengvaxia
PMID 37251387Vaccine development for mosquito-borne viral diseases.Frontiers in immunology2023name in abstract: CYD-TDV
PMID 37340460'I was terrified for my child': understanding the link between the Dengvaxia® controversy and the measles vaccine hesitancy in Pasay City, Philippines.Journal of public health (Oxford, England)2023name in title: Dengvaxia
PMID 37554332Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines.Frontiers in immunology2023name in title: Dengvaxia

NIH grants

ProjectTitleOrganisationPIYearsLinked by
I01CX002688Durability and mechanisms of dengue vaccine and infection mediated immunityST. LOUIS VA MEDICAL CENTERGEORGE, SARAH2024–2026name in abstract: Dengvaxia
P01AI106695Protective immunity following dengue virus natural infections and vaccinationUNIVERSITY OF CALIFORNIA BERKELEYHARRIS, EVA2020–2026name in abstract: Dengvaxia
R01AI161025Structure based design of dengue subunit vaccines for inducing protective but not disease enhancing antibodiesUNIV OF NORTH CAROLINA CHAPEL HILLDESILVA, ARAVINDA M.2022–2026name in project terms: Dengvaxia
R01AI170894A Novel T cell-based Vaccine to Prevent Dengue/Zika virus infectionGEORGIA STATE UNIVERSITYQIAO, LIANG2025–2026name in abstract: Dengvaxia
R01AI175495Identification of serological markers of protection and risk for dengue vaccines and natural infectionJOHNS HOPKINS UNIVERSITYCUMMINGS, DEREK A2023–2026name in project terms: Dengvaxia
R01AI179782Treating flaviviruses with mRNA-encoded Cas13EMORY UNIVERSITYSANTANGELO, PHILIP J2024–2026name in abstract: Dengvaxia
R01AI186073Long-term safety and effectiveness of Dengvaxia in the PhilippinesUNIVERSITY OF HAWAII AT MANOAWANG, WEI-KUNG2024–2026name in title: Dengvaxia
R01AI192605Analysis of innate responses and vaccination-induced serotype-specific B and T cell responses associated with protection against controlled human dengue virus challengeJOHNS HOPKINS UNIVERSITYBAILEY, JUSTIN RICHARD2026–2026name in project terms: Dengvaxia
R01AI198147Mechanistic analysis of a combined liposome-TLR7/8-agonist adjuvanted virus-like particle vaccineOREGON HEALTH & SCIENCE UNIVERSITYHIRSCH, ALEC J2026–2026name in project terms: Dengvaxia
R01AI201550Past encounters, Future protection: Harnessing immune imprinting for improved vaccinesYALE UNIVERSITYLUCAS, CAROLINA2026–2026name in project terms: Dengvaxia
R03AI193192Novel Antiviral Agents Targeting Zika and Dengue VirusBAYLOR COLLEGE OF MEDICINELI, XIN2025–2026name in project terms: Dengvaxia
R21AI197057Qdenga Vaccine: Assessment of immunogenicity in a longitudinal cohort studyYALE UNIVERSITYLUCAS, CAROLINA2026–2026name in project terms: Dengvaxia
R56AI150672Driving Protective Dengue Virus-Specific T and B Cell Responses Through VaccinationUNIVERSITY OF ILLINOIS AT CHICAGORICHNER, JUSTIN2026–2026name in project terms: Dengvaxia
U01AI179523Long-term durability of DENV-specific immunity after vaccination in a dengue-endemic populationUNIVERSITY OF RHODE ISLANDROTHMAN, ALAN L2024–2026name in abstract: CYD-TDV
U01AI186860A Phase 2b randomized open label trial to assess the quality and balance of dengue immunity elicited by prime-boost combinations of TAK-003 and Butantan-DVEMORY UNIVERSITYCOLLINS, MATTHEW2025–2026name in abstract: CYD-TDV
R01AI153500Maternal Antibody-Mediated Enhancement of Dengue PathogenesisLA JOLLA INSTITUTE FOR IMMUNOLOGYSHRESTA, SUJAN2021–2025name in project terms: Dengvaxia
R01AI156187Probing Functional States and Inhibition of Flaviviral Proteases Using Nanopore TweezersUNIVERSITY OF MASSACHUSETTS AMHERSTCHEN, MIN2021–2025name in abstract: Dengvaxia
R01AI158194Structure-based design of broad flavivirus immunogensALBERT EINSTEIN COLLEGE OF MEDICINELAI, JONATHAN R.2021–2025name in project terms: Dengvaxia
R01AI163188Development of a Replicon RNA-based Vaccine against Dengue and ZikaLA JOLLA INSTITUTE FOR IMMUNOLOGYSHRESTA, SUJAN2021–2025name in project terms: Dengvaxia
R44AI192180A Novel Cost-Effective Multispecific Therapeutic for DengueMAPP BIOPHARMACEUTICAL, INC.ZEITLIN, LARRY2025–2025name in abstract: Dengvaxia
ZIAAI001346Immunology, virology, and epidemiology of flaviviruses and other emerging virusesNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESKATZELNICK, LEAH2021–2025name in abstract: Dengvaxia
F30AI160898Age in dengue antibody response and risk after primary natural infectionUNIV OF NORTH CAROLINA CHAPEL HILLZHU, DEANNA2021–2024name in project terms: Dengvaxia
R01AI150672Dengue virus mRNA lipid nanoparticle vaccineUNIVERSITY OF ILLINOIS AT CHICAGORICHNER, JUSTIN2021–2024name in abstract: Dengvaxia
R01AI157491Sex ratio distortion in Aedes aegyptiVIRGINIA POLYTECHNIC INST AND ST UNIVTU, ZHIJIAN JAKE2020–2024name in abstract: Dengvaxia
R03AI171469An innovative and straightforward approach to construct and manipulate viral infectious clonesVIRGINIA POLYTECHNIC INST AND ST UNIVWEGER, JAMES D2023–2024name in abstract: Dengvaxia
R21AI178617Immunogenicity of the dengue vaccine CYD-TDV in a dengue virus serotype 1 immune populationOREGON HEALTH & SCIENCE UNIVERSITYMESSER, WILLIAM2023–2024name in title: CYD-TDV
U01AI134582A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic PopulationUNIVERSITY OF VERMONT & ST AGRIC COLLEGEKIRKPATRICK, BETH DIANE2022–2024name in project terms: Dengvaxia
U19AI181960Core E: Correlates of ProtectionWASHINGTON UNIVERSITYDIAMOND, MICHAEL S2024–2024name in project terms: Dengvaxia
ZIAAI001167CAP:Evaluation of a Dengue Vaccine in Adults with Preexisting Flavivirus ImmunityNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESWHITEHEAD, STEPHEN2017–2024name in abstract: Dengvaxia
R21AI156059Role of nonstructural protein in limited genetic diversity of yellow fever 17D vaccine virusUNIVERSITY OF TEXAS MED BR GALVESTONBARRETT, ALAN D.T.2022–2023name in project terms: Dengvaxia
U01AI141997Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue VaccineUNIVERSITY OF VERMONT & ST AGRIC COLLEGEDIEHL, SEAN A.2021–2023name in project terms: Dengvaxia
U19AI111825Immunity to dengue virusesROCKEFELLER UNIVERSITYWANG, TAIA2019–2023name in abstract: Dengvaxia
P01AI132132Zika virus pathophysiology during pregnancyUNIVERSITY OF WISCONSIN-MADISONO'CONNOR, DAVID H.2018–2022name in abstract: Dengvaxia
R01AI073755Antibody-based Protection against FlavivirsesWASHINGTON UNIVERSITYDIAMOND, MICHAEL S2021–2022name in project terms: Dengvaxia
R01AI132563Previous exposure to dengue as a risk factor for Zika during pregnancyUNIVERSITY OF MINNESOTAALIOTA, MATTHEW T2018–2022name in abstract: Dengvaxia
ZIAAI001347Epidemiology, immunology, and evolution of SARS-CoV-2 and other coronaviruses before and during the COVID-19 pandemicNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESKATZELNICK, LEAH2021–2022name in abstract: Dengvaxia
R21AI148836Bacteriophage virus-like particle vaccines against dengue virus non-structural protein 1UNIVERSITY OF NEW MEXICO HEALTH SCIS CTRFRIETZE, KATHRYN M.2020–2021name in abstract: Dengvaxia
R43AI145617Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health ThreatsPLEX PHARMACEUTICALS, INC.REMACLE, ALBERT2021–2021name in project terms: Dengvaxia
R01AI125198PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACYUNIV OF NORTH CAROLINA CHAPEL HILLDESILVA, ARAVINDA M.2016–2020name in abstract: CYD-TDV
R21AI145012The DKE-121 strain as a possible new Dengue virus serotypeWASHINGTON UNIVERSITYDIAMOND, MICHAEL S2019–2020name in abstract: Dengvaxia
ZIAAI000987Clinical Trials of Biodefense Vaccines (Dengue)NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESWHITEHEAD, STEPHEN2020–2020name in abstract: Dengvaxia
F31AI145408Computer-based Design of Dengue Virus Vaccine AntigensUNIV OF NORTH CAROLINA CHAPEL HILLKUDLACEK, STEPHAN2019–2019name in abstract: Dengvaxia
R21AI128681Rapid development and testing of Zika virus vaccine candidatesUNIVERSITY OF CONNECTICUT STORRSVERARDI, PAULO H2016–2017name in abstract: Dengvaxia
R56AI132563Previous exposure to dengue as a risk factor for Zika virus during pregnancyUNIVERSITY OF WISCONSIN-MADISONALIOTA, MATTHEW T2017–2017name in abstract: Dengvaxia

Notes

Dengvaxia: four live chimeric viruses on the yellow fever 17D-204 backbone, each carrying the prM and E genes of one dengue serotype. Counted as a vector because the administered virus is YF 17D carrying foreign (dengue) antigens and the immunity sought is against dengue, not yellow fever. EU authorisation withdrawn at the holder's request on 2025-10-21; first approvals were in Mexico and other endemic countries from December 2015 (no agency record opened for those, so only the EMA and FDA rows are recorded). NCIt search for 'Dengvaxia' returned no concept.

How to cite

CYD-TDV (AXP000206.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000206.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.